profit from every $100 of sales.
$0$100
Lexeo Therapeutics
$3.14+8.65% today
-61.7% in 1 year
1-year low $2.631-year high $10.63
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Lexeo Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $654,000 in 2022 to $0 in 2025, with -$100.0 million of profit last year.
SalesProfit
Lexeo Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Lexeo Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Lexeo Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1 | 0 | 0 | 0 | |
| – | – | – | – | |
| -61 | -69 | -106 | -109 | |
| -58 | -64 | -96 | -98 | |
| -59 | -66 | -98 | -100 | |
| -2.36 | -12.40 | -3.09 | -1.86 | |
| – | – | – | – | |
| -9,252.1% | – | – | – | |
| -9,063.8% | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 97 | 140 | 147 | 269 |
| Cash | 77 | 121 | 35 | 63 |
| Total debt | 13 | 12 | 10 | 8 |
| Total liabilities | 210 | 26 | 30 | 22 |
| -113 | 114 | 117 | 247 | |
| 25 | 5 | 32 | 54 | |
| – | -41.8% | -61.2% | -31.0% | |
| 52.5% | -58.5% | -84.2% | -40.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -55 | -59 | -81 | -99 | |
| 1 | 0 | 0 | 0 | |
| -55 | -60 | -82 | -99 | |
| Dividends paid | – | – | – | – |
| – | 0 | 0 | 0 | |
| 2 | 3 | 12 | 12 |
Valuation
- –
- –
- –
- 2.0×
- 394.1×
- –
- –
- -21.5%
- -23.0%
- 0.0%
Profitability
- 0.0%
- -9,252.1%
- -9,063.8%
- 0.0%
- -40.9%
- -3.8%
- -47.5%
- -35.0%
- -41.4%
- –
Growth
- –
- –
- −21.2%
- –
- +20.8%
Financial health
- -1.1×
- 0.03
- 2.9%
- -534.3×
- 14.16
- 14.16
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 11%of 948
Bottom 4%of 985
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | -0.25 | -0.29 | +13.8% |
| Mar 30, 2026 | -0.27 | -0.32 | +15.6% |
| Nov 5, 2025 | -0.33 | -0.48 | +31.2% |
| Aug 14, 2025 | -0.60 | -0.64 | +6.3% |
| May 12, 2025 | -0.99 | -0.80 | −23.7% |
| Mar 24, 2025 | -0.78 | -0.87 | +10.3% |
| Nov 13, 2024 | -0.89 | -0.65 | −36.9% |
| Aug 12, 2024 | -0.64 | -0.69 | +7.2% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
35No pass
Benjamin Graham
53No pass
Philip Fisher
34No pass
Peter Lynch
11No pass
Joel Greenblatt
0No pass
Charlie Munger
30No pass
Terry Smith
31No pass
Questions about Lexeo Therapeutics
Is Lexeo Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Lexeo Therapeutics AI analysis
What does Lexeo Therapeutics do?
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. It is in Biotechnology.
Does Lexeo Therapeutics pay a dividend?
No. Lexeo Therapeutics does not pay a dividend at the moment.
Is Lexeo Therapeutics stock halal?
No. Lexeo Therapeutics does not pass our halal screen: its cash and confirmed interest-bearing investments are 71% of its market value, at or above the 33% limit. How we check
How has Lexeo Therapeutics stock done over the past year?
Down 61.7% over the past twelve months, to $3.14. It traded between $2.63 and $10.63 and is 70.5% below its high.
Who are Lexeo Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Lexeo Therapeutics's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.